Soreide Law Group has been contacted by investors who purchased Gemphire Therapeutics Inc. (GEMP) and experienced stock losses through the sale of the stock brokers at Laidlaw and Company. Laidlaw is listed on their website as the “Co-Manager” from the March of 2017 offering. Often, securities that are newly issued are more volatile than the more established companies, and if the investor was not looking to speculate, this could have been a highly unsuitable recommendation given to you by your broker from Laidlaw and Company.
According to Yahoo Finance, Gemphire Therapeutics Inc. (GEMP), is a clinical-stage biopharmaceutical company, focusing on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH. The company was founded in 2008 and is headquartered in Livonia, Michigan.
In March of 2017, Gemphire Therapeutics Inc. (GEMP) was trading around 12.2 and today it is trading at approximately 5.94. The 52-week change is -39.88%.
On Laidlaw and Company’s website, the following information on their company is given:”Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets.”
If you or a family member have experienced investment losses in Gemphire Therapeutics Inc. (GEMP), due to the recommendation of your broker/financial advisor at Laidlaw and Company, call Soreide Law Group for a no cost consultation with an experienced securities lawyer regarding the possible recovery of your valuable financial losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents clients nationwide before FINRA. We operate on a contingency fee basis, no fee if no recovery.
.
FINRA barred securities broker Alan K. Ngo [CRD: 4273116, Freehold, New Jersey], given the publicly available information on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Ngo worked for PFS Investments Inc. from January 2, 2003, to November 25, 2025. See below to learn more about Ngo’s disclosures. FINRA Sanctioned Ngo For Failing To Comply During Investigation […]
FINRA barred securities broker Kevin Christopher McCarthy [CRD: 1702715, Hialeah, Florida], and investors complained about him, based on public information found on Financial Industry Regulatory Authority (FINRA) BrokerCheck. McCarthy worked for Madison Avenue Securities LLC from December 4, 2007, to January 30, 2026. Investors are encouraged to continue reading to find out more about McCarthy’s […]
FINRA barred securities broker Mohammed Anayet Karim [CRD: 4419277, Lakeland, Florida], according to publicly available information on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Karim worked for BB&T Securities LLC from September 24, 2018, to February 17, 2021, and Truist Investment Services Inc. from February 17, 2021, to August 8, 2025. See the following information to […]
Phone:
Fax: 1-954-760-6553
Email: info@securitieslawyer.com